Disclosure of Genetic Information and Change in Dietary Intake: A Randomized Controlled Trial

Daiva E. Nielsen, Ahmed El-Sohemy*

Department of Nutritional Sciences, University of Toronto, 150 College St, Toronto, ON, M5S 3E2, Canada

Abstract

Background: Proponents of consumer genetic tests claim that the information can positively impact health behaviors and aid in chronic disease prevention. However, the effects of disclosing genetic information on dietary intake behavior are not clear.

Methods: A double-blinded, parallel group, 2:1 online randomized controlled trial was conducted to determine the short- and long-term effects of disclosing nutrition-related genetic information for personalized nutrition on dietary intakes of caffeine, vitamin C, added sugars, and sodium. Participants were healthy men and women aged 20–35 years (n = 138). The intervention group (n = 92) received personalized DNA-based dietary advice for 12-months and the control group (n = 46) received general dietary recommendations with no genetic information for 12-months. Food frequency questionnaires were collected at baseline and 3- and 12-months after the intervention to assess dietary intakes. General linear models were used to compare changes in intakes between those receiving general dietary advice and those receiving DNA-based dietary advice.

Results: Compared to the control group, no significant changes to dietary intakes of the nutrients were observed at 3-months. At 12-months, participants in the intervention group who possessed a risk version of the ACE gene, and were advised to limit their sodium intake, significantly reduced their sodium intake (mg/day) compared to the control group (−287.3 ± 114.1 vs. 129.8 ± 118.2, p = 0.008). Those who had the non-risk version of ACE did not significantly change their sodium intake compared to the control group (12-months: −244.2 ± 150.2, p = 0.11). Among those with the risk version of the ACE gene, the proportion who met the targeted recommendation of 1500 mg/day increased from 19% at baseline to 34% after 12 months (p = 0.06).

Conclusions: These findings demonstrate that disclosing genetic information for personalized nutrition results in greater changes in intake for some dietary components compared to general population-based dietary advice.

Trial Registration: ClinicalTrials.gov NCT01353014

Citation: Nielsen DE, El-Sohemy A (2014) Disclosure of Genetic Information and Change in Dietary Intake: A Randomized Controlled Trial. PLoS ONE 9(11): e112665. doi:10.1371/journal.pone.0112665

Editor: Margaret M. DeAngelis, University of Utah, United States of America

Received June 30, 2014; Accepted September 17, 2014; Published November 14, 2014

Copyright: © 2014 Nielsen, El-Sohemy. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. Data are from the Toronto Nutrigenomics and Health study whose authors may be contacted at a.el.sohemy@utoronto.ca.

Funding: This study was supported by a grant from the Advanced Foods and Materials Network (AFMNet) and the Canadian Institutes of Health Research (CIHR; MOP-89829). AE-S holds a Canada Research Chair in Nutrigenomics. DEN is a recipient of an Ontario Graduate Scholarship and a Banting & Best Diabetes Centre Graduate Studentship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have read the journal’s policy and the authors of this manuscript have the following competing interests: AE-S holds shares in Nutrigenomix Inc., a genetic testing company for personalized nutrition. This does not alter the authors’ adherence to PLOS ONE policies on data sharing and materials.

* Email: a.el.sohemy@utoronto.ca

Introduction

Personal genetic information has become easily obtainable, in large part due to the advancement of the consumer genetic testing industry. As a result of the decreasing costs to carry out genotyping, individuals can now receive personalized feedback regarding their susceptibility to a number of different health conditions at a relatively low cost [1]. The impact that this information may have on health behaviors is of particular interest [2,3], since chronic diseases such as cardiovascular disease and type 2 diabetes have become major public health concerns. There is considerable evidence that these conditions are associated with a number of modifiable health behaviors such as diet, physical activity and smoking, but lifestyle interventions aimed at achieving positive health behavior changes are often ineffective at producing the long-term changes necessary to mitigate disease risk [4]. As a result, proponents of personalized medicine claim that health recommendations tailored to an individual’s genetic profile may be more effective at producing behavior change than generic population-based recommendations. A growing body of qualitative research shows strong public interest in genomics and personalized medicine for disease prevention [5–9], but there is limited quantitative evidence to support the claim that personalized genomics can be employed as a useful prevention tool.
The study of how human genetic variations modify an individual’s response to diet on various health outcomes, often referred to as nutrigenomics or nutrigenetics, is a key part of personalized medicine [10] because nutrition is arguably one of the most important modifiers of chronic disease risk [11]. Many direct-to-consumer genetic tests provide single nucleotide polymorphism (SNP)-based estimates of disease susceptibility that do not take into account environmental factors. For complex diseases, including diet-related chronic diseases, risk estimates based solely on genetic variation without consideration of environmental interactions can be inaccurate [12]. Therefore, genetic testing for personalized nutrition using modifier or metabolic genes may have the potential to be more useful than genetic testing for disease risk using disease susceptibility genes because the advice that is given from a personalized nutrition test is more specific and actionable than advice from a disease susceptibility test. Indeed, a previous study demonstrated that individuals consider DNA-based dietary advice to be more useful and understandable than general population-based dietary recommendations, and individuals report that they would be more motivated to change their diet if provided with personalized nutrition information based on their genetics [13]. Individuals who have had their genomes analyzed report that the genetic information impacted their dietary behaviors, although the genetic information they received was not necessarily linked to any specific dietary modification [14,15]. Despite this evidence, no previous study has examined the effect of disclosing personalized genetic information based on nutrigenomics testing on dietary intake behavior. In addition, previous studies investigating the impact of personal genomic information related to disease susceptibility on health behaviors have lacked long-term follow-up data. As a result, the short- and long-term effects of personal genomic information on health behaviors are largely unknown. Therefore, the objective of the present study was to determine the short- and long-term effects of disclosing genetic information for personalized nutrition on dietary intake in a population of young adults using a randomized controlled trial (Table 1).

Materials and Methods

Ethics Statement

Ethics approval was obtained from the University of Toronto Institutional Review Board and the study is registered with http://clinicaltrials.gov (NCT 01353014). All subjects provided written informed consent. The protocol for this trial and supporting CONSORT checklist are available as supporting information; see Checklist S1 and Protocol S1.

Study Design and Subjects

The present study was intended to mimic the nature of a direct-to-consumer genetic test such that all study materials were distributed and completed in the mail or electronically and no in-person contact was made with subjects for the present study. Details on the study design have been published elsewhere [13]. Briefly, subjects (n = 157) who had previously participated in a nutrigenomics research study and had provided a blood sample were invited to complete a 196-item, semi-quantitative Toronto-nutrigenomics research study and had provided a blood sample. Participants were informed that they would receive DNA-based dietary advice at some point during the study and those who were randomized to the control group were given the DNA-based advice after the final follow-up assessment was completed. Dietary intakes were self-reported by participants on the FFQ with no assistance from study personnel, and the nutrient analyses were made without knowledge of study group assignment. DNA was isolated from whole blood with the GenomicPrep Blood DNA Isolation kit (Amersham Pharmacia Biotech Inc, Piscataway, NJ) and genotyping was completed using either real-time polymerase chain reaction on an ABI 7000 Sequence Detection System (Applied Biosystems) or a multiplex restriction fragment length polymorphism (RFLP) polymerase chain reaction method, as described previously [16,17]. Genotyping was verified by using positive control subjects in each 96-well plate as well as a second genotyping of ~5% of a random selection of samples with 100% concordance.

Dietary Reports and Recommendations

Subjects in the intervention group were genotyped for variants that affect caffeine metabolism (CYP1A2) [18,19], vitamin C utilization (GSTM1) [17], sweet taste perception (TAS1R2) [20], and sodium-sensitivity (ACE) [21,22] (Table 1). These genes were selected as representative sample tests from consumer genetic testing companies, which are based on studies of gene-diet interactions using a candidate gene approach. Although newer experimental approaches such as genome-wide association studies (GWAS) are being used to identify genetic variants associated with disease susceptibility, to date only a few GWAS studies have investigated gene-diet interactions on health outcomes [23,24]. Thus, the purpose of the present study was to evaluate the behavioral response to disclosing genetic information, not to validate the clinical efficacy of the genetic variants provided in the dietary advice reports. Dietary reports were sent to all subjects by e-mail. The dietary report for subjects in the intervention group informed subjects of their genotypes and included a corresponding DNA-based dietary recommendation for daily intake of caffeine, vitamin C, added sugars and sodium (Nutrigenomix Inc., Toronto, Canada). Those who possessed the genotype that has been associated with increased risk of a health outcome when consuming above or below a certain daily amount were given a “targeted” dietary recommendation. For caffeine and sodium, this recommendation was more stringent than the current general...
Table 1. Prevalence of risk alleles in intervention group (n = 92) and associated risk.

| Dietary Component | Gene | Risk Allele | Non-Risk Allele | Associated Risk                                                                 |
|-------------------|------|-------------|-----------------|--------------------------------------------------------------------------------|
| Caffeine          | CYP1A2 | 48 (52)     | 44 (48)         | Increased risk of myocardial infarction and hypertension when consuming above 200 mg of caffeine/day |
|                   |       |             |                 | General recommendation: ≤300 mg/day for women of child-bearing age               |
|                   |       |             |                 | ≤400 mg/day for other adults                                                     |
| Vitamin C         | GSTM1 + GSTT1 | 52 (57) | 40 (43)         | Increased risk of serum ascorbic acid deficiency when consuming below the RDA for vitamin C |
|                   |       |             |                 | General recommendation: RDA<sup>a</sup> for women: ≥75 mg/day                   |
|                   |       |             |                 | RDA for men: ≥90 mg/day                                                          |
| Added Sugars      | TAS1R2 | 41 (45)     | 51 (55)         | Increased risk of over-consuming sugars                                         |
|                   |       |             |                 | General recommendation: ≤10% energy/day                                          |
| Sodium            | ACE   | 64 (70)     | 28 (30)         | Increased risk of sodium-sensitive hypertension when consuming above the AI for sodium |
|                   |       |             |                 | General recommendation: UL<sup>b</sup>: ≥2300 mg/day                           |
|                   |       |             |                 | Targeted Recommendation: AF: ≥1500 mg/day for those with risk version of ACE     |

<sup>a</sup>RDA: Recommended dietary allowance.
<sup>b</sup>UL: Tolerable upper intake level.
<sup>c</sup>AI: Adequate intake.

recommended for daily intake and was based on previous work that evaluated health outcomes according to genotype at different levels of intake [18,19,21,22]. For added sugars and vitamin C, subjects were informed to be particularly mindful of meeting the current general recommendation for daily intake, since no previous study has examined how individuals respond to consuming various levels of these nutrients according to genotype and, therefore, a different intake level could not be recommended. Subjects who possessed the genotype that has not been associated with increased risk received the current general recommendation for daily intake [25–27]. The control group was e-mailed a report of current general recommendations for the same nutrients without genetic information. Subjects were e-mailed a monthly reminder of their dietary report and additional FFQs were collected at 3- and 12-month follow-up assessments.

Study outcomes
The primary study outcome was change in dietary intakes of caffeine, vitamin C, added sugars, and sodium between the control and intervention groups from baseline to the follow-up assessments. Changes in dietary intakes were examined between baseline and 3-months to determine the short-term effects of the intervention, while changes in intakes between baseline and 12-months were examined to determine the long-term effects. The secondary study outcome was to compare the proportion of participants who met the recommendations for intake before and after the intervention for dietary components that significantly changed between the control and intervention groups.

Statistical Analyses
Statistical analyses were performed using the Statistical Analysis Software (version 9.2; SAS Institute Inc., Cary, NC). The α error was set at 0.05 and all reported p-values are two-sided. Subject characteristics between the intervention and control group were compared using a Chi-square test for categorical variables and a Student’s t-test for continuous variables. The distributions of nutrient intakes were examined and a log transformation was applied to those that deviated from normality. In these cases, the p-values from models using transformed values are reported, but untransformed means and measures of spread are reported to facilitate interpretation. Subjects who were likely under-reporters (consuming less than 800 kcal/day) were excluded from the analyses, since dietary intake data from these individuals may not have been reliable. Baseline mean intakes of vitamin C, sugar, sodium and caffeine were compared between ethnocultural groups using general linear models to determine if any significant dietary differences were present between groups at the start of the study. General linear models were also conducted to test for changes in dietary intakes between baseline and 3-months, and baseline and 12-months, in order to determine the effect of the dietary advice over a short- and long-term period. The Tukey-Kramer test for multiple comparisons was applied to determine whether any changes in intake of the intervention groups differed from the change in intake of the control group. The Chi-square test was used to compare the proportion of subjects meeting the recommendations for intake between baseline and the follow-up assessments. Fisher’s Exact Test was used if a proportion category consisted of fewer than 5 subjects.

Results
Subject Characteristics
Of the 157 subjects who were sent the baseline FFQ, 125 completed the 12-month study giving an overall retention rate of 80% (Figure 1). In relation to those who were randomized (n = 138), this represents 91% of subjects who completed the 12-month study.
The mean age of the participants was 26.5 ± 3.0 years and 78% were female. The study population was multi-ethnic with Caucasian, East Asian, and South Asian groups representing the majority of ethnic backgrounds. Over half of the population possessed at least an undergraduate degree. There were no significant differences between the characteristics of participants in the intervention group when compared to the control group (Table 2). However, a significant difference in baseline sodium intake (mg/day) was observed between the East Asian and Caucasian groups (1837 ± 147 vs. 2319 ± 88, p = 0.03). As a result, the general linear models examining changes in dietary intakes are adjusted for ethnocultural group. At baseline, the proportion of subjects who did not meet the general recommendation for caffeine, vitamin C, added sugars and sodium were 9%, 14%, 24% and 39%, respectively. Thirty eight percent of subjects did not meet the targeted recommendation (for those with elevated risk) for caffeine intake at baseline, while 80% did not meet the targeted recommendation for sodium intake. The targeted recommendation for vitamin C and added sugars was the same as the general recommendations.

Changes in Dietary Intakes

Of the 138 subjects who were randomized, 135 completed the 3-month follow-up and 130 were included in the 3-month analyses (n = 5 under-reporters excluded). At 12 months, 125 subjects completed the follow-up and 123 were included in the analyses (n = 2 under-reporters excluded). There were no differences in the baseline characteristics (e.g. age, proportion of males/females) between those who were included in the final analysis and those who were not. Compared to the control group, no significant changes from baseline were observed for intakes of caffeine, vitamin C, added sugars, or sodium at the 3-month follow-up among subjects in the intervention group who carried a risk version of the corresponding gene (intervention risk group) or among subjects who carried the non-risk version (intervention non-risk group). At the 12-month follow-up, subjects in the intervention group who were informed that they possessed the risk version of the \textit{ACE} gene, and who were given the targeted advice to consume below the Adequate Intake (AI) of 1500 mg/day of sodium, significantly reduced their mean sodium intake (mg/day) from baseline when compared to the control group.
Discussion

The present study is the first to evaluate the effects of disclosing genetic information related to personalized nutrition on dietary intake and the findings show that DNA-based dietary advice results in greater changes in intake for some dietary components compared to population-based dietary advice. Dietary modification is an important health behavior for chronic disease prevention. Changes in health behaviors have not been frequently reported in previous studies that have investigated the effect of disclosing genetic information related to disease risk [28–31] and a 2010 Cochrane review concluded that disclosing genetic risk information for disease has little impact on actual behavior, although it has a small effect on one’s intention to change [32]. However, the genomic information provided in those studies was related to disease susceptibility, not personalized nutrition, and the studies lacked a long-term follow-up assessment. Moreover, participants in previous studies were not provided with personalized recommendations on what behavioral strategies should be followed to mitigate disease risk. Results from the present study provide evidence that genetic testing for personalized nutrition may be more clinically useful for motivating favorable dietary changes than testing for disease susceptibility, since a change in sodium intake was observed after 12-months among those subjects who were informed that they were at greater genetic risk for cardiovascular disease reported that the addition of a vitamin E supplement was the most common change to vitamin or medication use among subjects who were informed that they possessed a risk allele, which is a limitation of the present study.

At the 12-month follow-up assessment 66% of subjects in the intervention risk group, 65% of subjects in the intervention non-risk group and 68% of subjects in the control group met the general recommendation for sodium intake (≤2300 mg/day). The mean change in sodium intake (mg/day) among subjects who were informed that they possessed the non-risk version of the ACE gene, and who were advised to follow the general recommendation for sodium intake, did not differ from the change in intake of the control group at 12-months (−244.2±150.2 vs. 129.8±118.2, p = 0.11). The mean change in intakes from baseline for caffeine, vitamin C and added sugars did not differ from the control group at the 12-month follow-up among either the intervention-risk or intervention non-risk groups (Table 3).

At the 12-month follow-up assessment 66% of subjects in the intervention risk group, 65% of subjects in the intervention non-risk group and 68% of subjects in the control group met the general recommendation for sodium intake of ≤2300 mg/day. In addition, 34% of subjects in the intervention risk group, 19% of subjects in the intervention non-risk group and 24% of subjects in the control group met the targeted recommendation for sodium intake of ≤1500 mg/day. These proportions were not significantly different between the control and intervention groups. Among those in the intervention group who had the risk version of the ACE gene, 19% met the targeted recommendation of ≤1500 mg/day at baseline compared to 34% after 12 months (p = 0.06), and 59% met the general recommendation of ≤2300 mg/day at baseline compared to 66% after 12 months (p = 0.41).

Table 2. Participant characteristics.

|                        | Intervention (n = 92) | Control (n = 46) | p-value |
|------------------------|-----------------------|-----------------|---------|
| n ( %)                 |                       |                 |         |
| Age (years)*           | 27±3                  | 26±3            | 0.82    |
| Female                 | 69 (75)               | 37 (80)         | 0.48    |
| Ethnicity              |                       |                 |         |
| Caucasian              | 59 (64)               | 24 (52)         | 0.18    |
| East Asian             | 19 (21)               | 12 (26)         | 0.47    |
| South Asian            | 9 (10)                | 6 (13)          | 0.56    |
| Other                  | 5 (5)                 | 4 (9)           | 0.46    |
| Education              |                       |                 |         |
| Some college or undergraduate training | 9 (10) | 8 (17) | 0.20   |
| College or undergraduate degree | 50 (54) | 22 (48) | 0.47   |
| Graduate degree        | 33 (36)               | 16 (35)         | 0.90    |

*Values shown are mean ± standard deviation.

doi:10.1371/journal.pone.0112665.t002

At the 12-month follow-up assessment 66% of subjects in the intervention risk group, 65% of subjects in the intervention non-risk group and 68% of subjects in the control group met the general recommendation for sodium intake (≤2300 mg/day). The mean change in intake of the control group at 12-months was not significantly different between the control and intervention groups. Among those in the intervention group who had the risk version of the ACE gene, 19% met the targeted recommendation of ≤1500 mg/day at baseline compared to 34% after 12 months (p = 0.06), and 59% met the general recommendation of ≤2300 mg/day at baseline compared to 66% after 12 months (p = 0.41).

Although changes were observed in dietary intakes of sodium among the intervention-risk group of subjects at the 12-month follow-up, no changes in intake of caffeine, vitamin C or added sugars were observed at either follow-up assessment. This may be due to the baseline intakes of these nutrients that were already mostly in line with the recommendations that were given to the subjects who possessed a risk allele, which is a limitation of the present study. Nevertheless, variants in other genes involved in reward pathways may play a role in one’s ability to reduce consumption of some of these dietary components [16,35]. Indeed, the National Human Genome Research Institute has recommended investigation into the potential for genomic information to improve behavior change interventions by customizing interventions to individuals based on genetic markers of adherence [36,37]. Despite the lack of an intervention effect on intake of these three dietary components in the present study, it is worth noting that subjects who possessed a non-risk allele for the corresponding genes did not shift to a less desirable level of intake by increasing...
Table 3. Changes in dietary intake after 3-months and 12-months.

|                        | Baseline (n = 133) | 3-months (n = 130) | 12-months (n = 123) |
|------------------------|-------------------|-------------------|-------------------|
|                        | n | Mean ± SEM | p-value\(^a\) compared to control group | n | Mean change ± SEM | p-value\(^a\) compared to control group | n | Mean change ± SEM | p-value\(^a\) compared to control group |
| Caffeine (mg/day)      |   |           |                               |   |           |                               |   |           |                               |
| Intervention risk      | 46 | 181.4±16.8 | 0.82                          | 45 | -3.0±14.8 | 0.61                          | 41 | -18.9±18.8 | 0.92                          |
| Intervention non-risk  | 44 | 194.8±17.8 | 0.92                          | 43 | -24.7±15.3 | 0.66                          | 41 | 1.5±19.4   | 0.99                          |
| Control                | 43 | 183.5±16.3 | 0.92                          | 42 | -7.3±14.8 | 0.92                          | 41 | -0.3±17.8 | 0.92                          |
| Vitamin C (mg/day)     |   |           |                               |   |           |                               |   |           |                               |
| Intervention risk      | 50 | 197.3±33.6 | 0.85                          | 49 | 49.5±37.6 | 0.99                          | 45 | 36.6±43.1 | 0.73                          |
| Intervention non-risk  | 40 | 226.2±35.1 | 0.96                          | 39 | -13.9±38.4 | 0.22                          | 37 | -58.4±43.5 | 0.42                          |
| Control                | 43 | 220.0±31.9 | 0.96                          | 42 | 44.1±37.1 | 0.96                          | 41 | -21.4±40.1 | 0.96                          |
| Added sugars (%/e/day) |   |           |                               |   |           |                               |   |           |                               |
| Intervention risk      | 38 | 8.9±0.8    | 0.99                          | 37 | -0.9±0.9  | 0.18                          | 33 | 0.4±0.9    | 0.98                          |
| Intervention non-risk  | 52 | 8.3±0.7    | 0.54                          | 51 | 0.5±0.8   | 0.99                          | 49 | -0.4±0.8   | 0.85                          |
| Control                | 43 | 9.3±0.7    | 0.85                          | 42 | 0.6±0.8   | 0.85                          | 41 | -0.4±0.8   | 0.85                          |
| Sodium (mg/day)        |   |           |                               |   |           |                               |   |           |                               |
| Intervention risk      | 63 | 2144.5±124.4 | 0.51                          | 62 | -143.0±109.0 | 0.20                          | 56 | -287.3±114.1 | 0.008                          |
| Intervention non-risk  | 27 | 2224.9±171.0 | 0.31                          | 26 | 97.8±145.6 | 0.97                          | 26 | -244.2±150.2 | 0.11                          |
| Control                | 43 | 2000.8±131.2 | 0.31                          | 42 | 82.2±119.2 | 0.97                          | 41 | 129.8±118.2 | 0.97                          |

\(^a\)p-values are for log-transformed values. Results are adjusted for ethnicity.

doi:10.1371/journal.pone.0112665.t003
communicating results of tests for high penetrance genes that may consumer whereas a genetic counselor would be better suited for consumer. If the results of a genetic test require dietary more appropriate than providing such information direct-to-consumer. Another limitation of the present study is the use of a FFQ to assess dietary intake, which is more useful in larger, population-based studies, as it provides a measure of relative intake rather than actual intake. However, the objective of the present study was to assess change in dietary intakes, which is a relative measure of intake. In addition, the sample size was small, yet comparable to previous studies examining the impact of disclosing genetic information on particular health behaviors [30,33,34], and subjects were highly educated and recruited from a previous nutrigenomics study. The reported reduction of nearly 300 mg of sodium per day in the intervention risk group was not sufficient to reduce the average sodium intake to the AI of 1500 mg/day, which was the targeted recommendation provided in the dietary report. Nevertheless, a recent Institute of Medicine report concluded that there is no benefit to sharply restricting sodium intake to the level of the AI [39] and a 2010 computer-simulated model examining the effect of dietary salt reduction on future cardiovascular disease projected that a 1 g/day reduction in average population salt intake, which is equivalent to about 400 mg/day of sodium, would prevent up to 28,000 deaths from any cause and would be more cost-effective than using medications to manage hypertension [40]. Therefore, the approximate 300 mg/day reduction in sodium intake reported in the present study would be considered clinically relevant.

Strengths of the present study are the inclusion of a control group, which provided a method of comparing the utility of DNA-based personalized nutritional advice on dietary intake to population-based recommendations, and the randomized design, which minimizes the potential for confounding effects. Including a 3- and 12-month follow-up assessment enabled us to examine the short- and long-term effects of the intervention. The finding that sodium intake was significantly reduced compared to the control group after 12-months among subjects in the intervention group with the risk version of the ACE gene suggests that longer-term studies are required to fully determine the impact of disclosing genetic information. Moreover, conducting the present study so that it closely resembles a consumer genetic test increases the validity of the findings to reflect the real world effects among consumer genetic test users. Early adopters of consumer genetic testing are more likely to be highly educated and Caucasian, with a substantial proportion of users between the ages of 18–49 years [15,28,41]. One study has reported a larger proportion of female consumers [41]. As a result, the subjects in the present study are representative of the early adopters of consumer genetic testing.

The present study was the first to empirically test the effect of DNA-based personalized nutritional advice on dietary intake behavior compared to population-based dietary advice. The findings show that DNA-based dietary advice can impact dietary intake to a greater extent than general population-based recommendations and provide supportive evidence for the clinical utility of personalized nutrition to assist in chronic disease prevention.

Supporting Information

Checklist S1 CONSORT Checklist. (DOC)

Protocol S1 Trial Protocol. (DOCX)

Acknowledgments

The authors thank Alyssa Katzikowski, Maria Tassone, and Sarah Shih for their assistance with subject recruitment and data collection.

Author Contributions

Conceptualized and designed the experiments: AE-S DEN. Performed the experiments: DEN. Analyzed the data: DEN. Contributed reagents/materials/analysis tools: AE-S. Wrote the paper: DEN AE-S.

References

1. Caulfield T, McGuire AL (2012) Direct-to-consumer genetic testing: perceptions, problems, and policy responses. Annu Rev Med 63: 23–33.
2. McBride CM, Koehly LM, Sanderson SC, Kaphingst KA (2010) The behavioral response to personalized genetic information: will genetic risk profiles motivate individuals and families to choose more healthful behaviors? Annu Rev Public Health 31: 89–103.
3. Christensen KD, Green RC (2013) How could disclosing incidental information from whole-genome sequencing affect patient behavior? Pers Med 10: 377–386.
4. Desroches S, Lapointe A, Ratte S, Gravel K, Legare F, et al. (2011) Interventions to enhance adherence to dietary advice for preventing and managing chronic diseases in adults: a study protocol. BMC Public Health 11: 111.
5. Leighton JW, Valverde K, Bernhardt BA (2011) The general public’s understanding and perception of direct-to-consumer genetic test results. Public Health Genomics 15: 11–21.
6. Cherkas LF, Harris JM, Levinson E, Spector TD, Prainsack B (2010) A survey of UK public interest in internet-based personal genome testing. PLoS One 5: e13473.
7. Goddard KA, Duquette D, Zlot A, Johnson J, Annis-Emeott A, et al. (2009) Public awareness and use of direct-to-consumer genetic tests: results from 3 state population-based surveys. Am J Public Health 99: 442–445.
8. Stewart-Knox BJ, Bunting BP, Gilpin S, Parr HJ, Pinhao S, et al. (2009) Attitudes toward genetic testing and personalized nutrition in a representative sample of European consumers. Br J Nutr 101: 982–989.
9. Kolor K, Duquette D, Zlot A, Foland J, Anderson B, et al. (2012) Public awareness and use of direct-to-consumer personal genomic tests from four state population-based surveys, and implications for clinical and public health practice. Genet Med 14: 860–867.
10. Kaput J (2008) Nutrigenomics research for personalized nutrition and medicine. Curr Opin Biotechnol 19: 110–120.
11. Nielsen DE, El-Sohemy A (2012) Applying genomics to nutrition and lifestyle modification. Pers Med 9: 739–749.
12. Wesselius A, Zeegers MP (2013) Direct-to-consumer genetic testing. OA Epidemiology. 1:4.
13. Nielsen DE, El-Sohemy A (2012) A randomized trial of genetic information for personalized nutrition. Genes Nutr 7: 559–566.
14. Maher B (2011) Nature readers flirt with personal genomics. Nature 478: 19.
15. Kaufman DJ, Bollinger JM, Dyvskin RL, Scott JA (2012) Risky business: risk perception and the use of medical services among customers of DTC personal genetic testing. J Genet Couns 21: 413–422.
16. Emery KM, Corey PN, El-Sohemy A (2009) Dopamine D2 receptor genotype (C957T) and habitual consumption of sugars in a free-living population of men and women. J Nutrigenet Nutrigenomics 2: 235–242.
17. Cahill LE, Fontaine-Bisson B, El-Sohemy A (2009) Functional genetic variants of glutathione S-transferase protect against serum ascorbic acid deficiency. Am J Clin Nutr 90: 1411–1417.
18. Cornelis MC, El-Sohemy A, Kabagambe EK, Campos H (2006) Coffee, CYP1A2 genotype, and risk of myocardial infarction. JAMA 293: 1135–1141.
19. Palatini P, Ceolotto G, Ragazzo F, Dorigatti F, Saladini F, et al. (2009) CYP1A2 genotype modifies the association between coffee intake and the risk of hypertension. J Hypertens 27: 1594–1601.

20. Eny KM, Wolever TM, Corey PN, El-Sohemy A (2010) Genetic variation in TAS1R2 (Ile191Val) is associated with consumption of sugars in overweight and obese individuals in 2 distinct populations. Am J Clin Nutr 92: 1501–1510.

21. Giner V, Poch E, Bragulat E, Oriola J, Gonzalez D, et al. (2000) Renin-angiotensin system genetic polymorphisms and salt sensitivity in essential hypertension. Hypertension 35: 512–517.

22. Poch E, Gonzalez D, Giner V, Bragulat E, Coca A, et al. (2001) Molecular basis of salt sensitivity in human hypertension. Evaluation of renin-angiotensin-aldosterone system gene polymorphisms. Hypertension 38: 1204–1209.

23. He J, Kelly TN, Zhao Q, Li H, Huang J, et al. (2013) Genome-wide association study identifies 11 novel loci associated with blood pressure responses to interventions in Han Chinese. Circ Cardiovasc Genet 6: 598–607.

24. Hamza TH, Chen H, Hill-Burns EM, Rhodes SL, Montimurro J, et al. (2011) Genome-wide gene-environment study identifies glutamate receptor GRIN2A as a Parkinson’s disease modifier gene via interaction with coffee. PLoS Genet 7: e1002377.

25. Nawrot P, Jordan S, Eastwood J, Rotstein J, Hugenholtz A, et al. (2003) Effects of caffeine on human health. Food Addit Contam 20: 1–30.

26. National Research Council (2006) Dietary Reference Intakes: The Essential Guide to Nutrient Requirements. The National Academies Press: Washington, DC.

27. Nishida C, Uauy R, Kumanyika S, Shetty P (2004) The joint WHO/FAO expert consultation on diet, nutrition and the prevention of chronic diseases: process, product and policy implications. Public Health Nutr 7: 245–250.

28. Bloss CS, Schork NJ, Topol EJ (2011) Genomic information as a behavioral health intervention: can it work? Per Med 8: 659–667.

29. Collier R (2012) Predisposed to risk but not change. CMAJ 184: E407–408.